An AnnData object for the Stereo-seq axolotl subset (30DPI, 60DPI and Adult) data from Wei et al.The Stereo-seq axolotl data [Wei et al., 2022] are available in the Spatial Transcript Omics DataBase (STOmics DB) under https://db.cngb.org/stomics/ artista/.

This entry provides access to processed CODEX data files of four studies analyzed in the article "Discovery and Generalization of Tissue Structures from Spatial Omics Data". Details of datasets can be found in the STAR Methods section of the article.

For each dataset, a zip file containing multiple comma-separated values (CSV) files is included.

Each region is assigned an unique identifier (e.g., DKD_kidney_001), and its related data files are:

{region_id}.cell_data.csv, a table containing three columns: "CELL_ID", "X", and "Y". This table provides centroid locations for all cells segmented in this region.

{region_id}.expression.csv, a table containing multiple columns: "CELL_ID", "DAPI", "CD45", etc. This table provides detailed protein biomarker expression quantified for all cells in this region.

{region_id}.scgp_annotations.csv, a table containing two columns: "CELL_ID" and "SCGP". This table provides SCGP/SCGP-Extension annotations for all cells in this region.

Code base for SCGP is also included in this entry. Please refer to https://gitlab.com/enable-medicine-public/scgp for the latest codes, questions, and/or issues. Raw CODEX data and images will be accessible through links posted at the code base. Raw data will also be available from lead contact (A.E.T.) upon request.

According to Cognitive Market Research, the global spatial OMICS market size will be USD 396.6 million in 2024. It will expand at a compound annual growth rate (CAGR) of 15.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 158.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 118.98 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 91.22 million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 19.83 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 7.93 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.7% from 2024 to 2031.
The spatial transcriptomics category held the highest spatial OMICS market revenue share in 2024.

Market Dynamics of Spatial OMICS Market

Key Drivers for Spatial OMICS Market

Rising Applications of Spatial Omics to Increase the Demand Globally

Spatial omics are facilitating the growing emphasis on personalized and precision medicine, which customizes treatments to unique patient traits. The field of spatial omics has seen a surge in medical usage because of technological improvements such as multiplexed analysis platforms and high-resolution imaging, which have enhanced accessibility and utility in clinical settings. Spatial omics is becoming more and more relevant in a variety of medical domains due to its developing therapeutic applications in infectious diseases, neurology, and genetic disorders. Over the course of the forecast period, the worldwide spatial OMICS market is predicted to grow as more applications for the technology are found and its adoption increases.

Increased Prevelance of Genetic Disorders to Propel Market Growth

The market for spatial omics is anticipated to rise at a rapid pace due to the increased frequency of genetic disorders. Disorders resulting from anomalies in a person's DNA that are inherited from one or both parents are referred to as genetic diseases. The prevalence of genetic illnesses is rising as a result of improved diagnostic methods, altered lifestyles, elevated awareness, and environmental variables that cause mutations. Because spatial omics technologies provide detailed spatial maps of molecular and genetic properties inside tissues, they provide a powerful tool for researching genetic disorders. For instance, in February 2023, congenital illnesses were expected to be the cause of 240,000 baby deaths worldwide within 28 days after birth each year by the World Health Organization (WHO), a specialized organization of the United Nations based in Switzerland that oversees international public health.

Restraint Factor for the Spatial OMICS Market

Challenges with Data Handling and Standards to Limit the Sales

The market for spatial OMICS is severely constrained by the difficulties in managing the large and complicated datasets that this technology generates. Gene expression levels, cellular interactions, and spatial coordinates are among the vast amounts of multi-dimensional data that spatial OMICS produces. It takes a lot of computer power, specialized software, and knowledgeable data scientists to manage and analyze these kinds of data. Particularly for smaller research organizations or businesses with low funding, the difficulties in data storage, transport, and analysis can be a significant impediment. The market's growth may be constrained by these data handling issues, which can cause delays, higher operating expenses, and impeded decision-making processes.

Slow implementation of technology restrains the market growth 

Among the major constraints restraining the development of the spatial optics market is complexity and limited integration of cutting-edge genomic technologies such as Next-Generation Sequencing (NGS) into healthcare. In spite of the promise held by NGS and supporting technologies such as single-cell genome sequencing, several issues remain which limit their glob...

Test datasets for omero-vitessce

Dataset designed for testing the omero-vitessce (https://github.com/NFDI4BIOIMAGE/omero-vitessce) plugin for OMERO (https://www.openmicroscopy.org/omero/). The omero-vitessce repository contains a cropped version of this dataset for automated testing (https://github.com/NFDI4BIOIMAGE/omero-vitessce/tree/main/test/data/MB266).

Files

• MAX_MBEN_ff_Xenium_0018446_MB-266_DAPI_2024-01-23_12.47.34_Fused_405nm_corr_cropped.png = PNG image with the DAPI channel.
• MAX_MBEN_ff_Xenium_0018446_MB-266_DAPI_2024-01-23_12.47.34_Fused_405nm_corr_cropped_cp_masks.png= Cell segmentation mask pixel values correspond to cell identities, 0 = background).
• cells.csv =
• embeddings.csv = UMAP embeddings for drawing an interactive scatterplot.
• feature_matrix.csv = Transcript counts in each cell.
• transcripts.csv = Gene name and coordinates (pixel) of each transcript.
• VitessceConfig.json = Example configuration file generated by the omero-vitessce plugin for the Vitessce, an equivalent file can be generated by using the form provided by the plugin in OMERO.web.

See the repository README file for more details on the formats of these files: https://github.com/NFDI4BIOIMAGE/omero-vitessce?tab=readme-ov-file#config-files

Usage

1. Add the omero-web-zarr and omero-vitessce plugins to your OMERO.web installation.
2. Import the images into OMERO in the same dataset.
3. Attach all the .csv data files.
4. Use the form in the "Vitessce" tab of the right-panel to generate a configuration file and open the Vitessce viewer.

See the repository README file for more details on usage (https://github.com/NFDI4BIOIMAGE/omero-vitessce?tab=readme-ov-file#usage) and installation (https://github.com/NFDI4BIOIMAGE/omero-vitessce?tab=readme-ov-file#installation)

Data Sources

Adapted from the full original data at: https://www.ebi.ac.uk/biostudies/bioimages/studies/S-BIAD1093 (10.6019/S-BIAD1093).

The original data were produced and analysed in the course of this study:

https://www.biorxiv.org/content/10.1101/2024.04.03.586404v1

Our files include the raw data from single-cell RNA sequencing, spatial transcriptomics sequencing conducted in our study. The raw data of the paper "Deciphering radial glial stem-like cells based on spatial multi-omics guides safe therapy in glioma".

The spatial omics market, encompassing spatial transcriptomics, spatial proteomics, and spatial genomics, is experiencing robust growth, driven by advancements in technology and increasing demand for high-resolution biological data. The market's ability to provide spatially resolved insights into biological processes is revolutionizing fields like drug discovery, diagnostics, and fundamental biological research. This detailed understanding of cellular organization and interaction at a single-cell level offers unprecedented opportunities for personalized medicine, enabling more precise diagnoses and targeted therapies. Key application areas include laboratory research, academic institutions, and increasingly, the pharmaceutical and biotechnology industries. The market is characterized by a diverse range of players, from established industry giants like PerkinElmer and Danaher Corporation to innovative startups such as Vizgen Corporation and S2 Genomics, indicating a dynamic and competitive landscape. Growth is further fueled by collaborations between these companies and research institutions, accelerating technological advancements and driving market expansion. While precise market sizing requires specific data points, considering a hypothetical CAGR of 15% (a reasonable estimate for a rapidly growing technology sector like this) and a 2025 market size of $500 million, we can project significant expansion over the forecast period. This growth will be fueled by ongoing technological innovation, particularly in the areas of higher throughput, improved sensitivity, and reduced cost of spatial omics assays. Geographic expansion, especially in developing economies with rising research infrastructure, will also contribute significantly. However, factors such as the high cost of instruments and reagents, the need for specialized expertise, and data analysis complexity pose potential restraints on broader market adoption. Despite these challenges, the transformative potential of spatial omics suggests a promising trajectory with considerable future growth potential.

The global spatial OMICS market is poised to witness significant growth, with a market size of USD 335.60 million in 2025 and projected to reach USD 884.07 million by 2033, exhibiting a CAGR of 10.60% during the forecast period. This growth is attributed to increasing demand for precision medicine, advancements in spatial technologies, and rising adoption of spatial OMICS in drug discovery and development. Key drivers of the spatial OMICS market include the rise of single-cell analysis, the need for a deeper understanding of tissue heterogeneity, and the increasing availability of spatial data. Furthermore, the development of novel spatial technologies such as spatial transcriptomics and spatial genomics is expected to further fuel market growth. However, factors such as high costs associated with spatial OMICS and a lack of skilled professionals may restrain market expansion. Recent developments include: March 2024: 10x Genomics initiated commercial distribution of its eagerly anticipated Visium HD Spatial Gene Expression instrument. Visium HD is engineered to empower researchers with the ability to thoroughly analyze FFPE tissue samples by quantifying spatial gene expression across the entire transcriptome at a single-cell resolution., January 2024: SimBioSys obtained 510(k) clearance from the US Food and Drug Administration (FDA). This clearance permits the marketing of TumorSight Viz, a software application designed to generate three-dimensional spatial visualizations of breast tumors.. Key drivers for this market are: High Burden of Cancer and Genetic Diseases, Advancement in Omics Technologies and Increasing Demand for Personalized Medicine; Rising Government Initiatives and Funding Activities. Potential restraints include: High Cost of Instruments and Data Storage, Complex Regulatory Requirement and Standardization Issues. Notable trends are: The Spatial Transcriptomics Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

The spatial multi-omics market is experiencing robust growth, driven by advancements in technology enabling simultaneous analysis of multiple omics data types (genomics, transcriptomics, proteomics) within a tissue's spatial context. This provides unprecedented insights into complex biological processes and disease mechanisms, surpassing the limitations of traditional bulk omics techniques. The market's expansion is fueled by increasing research funding in areas like oncology, immunology, and neuroscience, where understanding spatial organization is crucial for developing targeted therapies and diagnostics. The adoption of spatial multi-omics is accelerating across various applications, including hospital-based diagnostics, pharmaceutical research and development, and academic research centers. Technological innovations, such as improved imaging techniques, higher throughput platforms, and user-friendly data analysis software, are further driving market penetration. While high initial costs of instrumentation and the need for specialized expertise pose challenges, the rapidly decreasing costs and expanding user base are mitigating these restraints. The market is segmented by application (hospital, research center, others) and technology type (spatial transcriptomics, spatial proteomics), with spatial transcriptomics currently holding a larger market share but spatial proteomics expected to witness faster growth in the coming years due to its ability to provide functional insights alongside gene expression data. Key players like 10x Genomics, NanoString Technologies, and Akoya Biosciences are actively shaping the market through continuous innovation and strategic partnerships. The forecast period (2025-2033) anticipates substantial market expansion, fueled by the increasing awareness of spatial multi-omics' potential and its integration into clinical workflows. Regional variations exist, with North America and Europe currently dominating the market due to robust healthcare infrastructure and advanced research capabilities. However, emerging economies in Asia-Pacific are poised for significant growth, driven by increasing research funding and a growing understanding of the technology's potential. The competitive landscape is dynamic, featuring both established players and emerging companies, leading to continuous innovation and fostering healthy competition. This competitive environment coupled with sustained technological advancements promises further market expansion and refinement of the spatial multi-omics technology, improving access and driving down the overall cost.

Multimodal analysis of spatial transcriptomics (ST) and spatial metabolomics (SM) has rapidly advanced for characterizing tissue microenvironments. However, integrating ST and SM data remains challenging due to differing morphologies, resolutions, and batch effects. We developed SpatialMETA (Spatial Metabolomics and Transcriptomics Analysis), a novel method for integrating spatial multi-omics data, which aligns ST and SM to a unified resolution, enables both cross-modal and cross-sample integration to identify ST-SM associated spatial patterns, and provides extensive visualization and analysis capabilities. The datasets for SpatialMETA is avaiable.

Overview

New York, NY – April 08, 2025 – Global Spatial OMICS Market size is expected to be worth around USD 1009.6 million by 2033 from USD 364.2 million in 2023, growing at a CAGR of 10.7% during the forecast period 2024 to 2033.

Spatial Omics is an emerging field in molecular biology that combines spatial information with high-throughput omics technologies such as genomics, transcriptomics, and proteomics. It enables researchers to map cellular activity within the anatomical context of tissues, offering unprecedented insights into how cells interact in their native microenvironment.

Unlike traditional omics approaches, which analyze homogenized tissue samples, spatial omics retains spatial resolution, allowing scientists to study the location-specific expression of genes and proteins. This technology has become a critical tool in areas such as cancer research, neuroscience, immunology, and developmental biology.

Recent advancements in imaging, sequencing, and data analytics have significantly accelerated the growth of this field. Technologies such as spatial transcriptomics and multiplexed imaging are driving innovation, helping uncover cellular heterogeneity and complex biological mechanisms that were previously undetectable.

The market for spatial omics is witnessing rapid growth due to its potential in precision medicine and biomarker discovery. It is expected to transform diagnostics, drug development, and personalized treatment strategies. As the demand for spatially resolved molecular data continues to rise, spatial omics stands at the forefront of next-generation biological research, paving the way for more targeted and effective healthcare solutions.
https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_717/https://market.us/wp-content/uploads/2024/08/Spatial-OMICS-Market-Size.jpg" alt="Spatial OMICS Market Size" width="800" height="500">

Human breast cancer OMICs data generated for the publication "Solid phase capture and profiling of open chromatin by spatial ATAC"

Abstract from the publication: Current methods for epigenomic profiling are limited in the ability to obtain genome wide information with spatial resolution. Here we introduce spatial ATAC, a method that integrates transposase-accessible chromatin profiling in tissue sections with barcoded solid-phase capture to perform spatially resolved epigenomics. We show that spatial ATAC enables the discovery of the regulatory programs underlying spatial gene expression during mouse organogenesis, lineage differentiation and in human pathology.

Dataset description The dataset includes spatially-resolved chromatin accessibility profiling performed on three fresh-frozen tissue sections of HER2+ breast cancer. We provide raw data in the form of fastq files, along with processed feature barcode matrices, metadata, and photomicrographs of the tissue slices. Additionally the dataset contains spatially-resolved gene expression profiling of tissue sections from the same specimen. For this too, we provide raw and processed data, along with the metadata information.

Spatial transcriptomics data were generated using 10X Genomics' Visium platform, while spatial ATAC data were created using a method introduced in our publication, which relies on an analogous workflow. Samples were sequenced on Illumina Nextseq 550 or 2000 and raw data were processed with CellRanger Gene Expression or ATAC-seq pipelines.

To apply for conditional access to the dataset, please contact datacentre@scilifelab.se.

Mass spectrometry imaging (MSI) allows investigating the spatial distribution of chemical compounds directly in biological tissues. As the analytical depth of MSI is limited, MSI needs to be coupled to more sensitive local extraction-based omics approaches to achieve a comprehensive molecular characterization. For this it is important to retain the spatial information provided by MSI for follow-up omics studies. It has been shown that regiospecific MSI data can be used to guide a laser microdissection system (LMD) for ultra-sensitive LC-MS analyses. So far, this combination has required separate and specialized MS instrumentation. Recent advances in dual-source instrumentation, harboring both MALDI and ESI sources, promise state-of-the-art MSI and liquid-based proteomic capabilities on the same MS instrument. In this study, we demonstrate that such an instrument can offer both, fast lipid-based MSI at high mass- and high lateral resolution, and sensitive LC-MS on local protein extracts from the exact same tissue section.

The Spatial Omics market, valued at $335.60 million in 2025, is poised for significant growth, exhibiting a Compound Annual Growth Rate (CAGR) of 10.60% from 2025 to 2033. This robust expansion is driven by several key factors. Advancements in technologies like spatial transcriptomics, spatial genomics, and spatial proteomics are providing researchers with unprecedented insights into the spatial organization of biological systems. This detailed understanding is crucial for accelerating drug discovery and development, enabling more precise diagnostics, and advancing translational research. The increasing adoption of single-cell analysis techniques further fuels market growth, as researchers strive to understand cellular heterogeneity and interactions within tissues and organs. Furthermore, the growing demand for high-throughput screening and personalized medicine is creating a strong pull for these technologies across pharmaceutical and biotechnology companies as well as academic research institutions. The availability of comprehensive software solutions for data analysis and interpretation is also a significant contributing factor, simplifying the complex data generated by these technologies. The market segmentation reveals a diverse landscape. Instruments currently dominate the product segment, reflecting the high capital expenditure associated with acquiring advanced spatial omics platforms. However, consumables and software are expected to experience substantial growth, driven by increasing research activity and the continuous need for reagents and analytical tools. Formalin-Fixed Paraffin-Embedded (FFPE) samples currently hold a significant share, leveraging existing pathology workflows. However, fresh frozen samples are gaining traction due to their superior preservation quality for certain applications. In terms of applications, diagnostics is a rapidly growing segment, promising to revolutionize personalized medicine by allowing for spatially-resolved diagnoses of diseases. North America currently holds a major share of the market, benefiting from a strong presence of key players and robust funding for biomedical research. However, Asia Pacific is projected to witness significant growth driven by increasing investment in life sciences and healthcare infrastructure. The competitive landscape is marked by the presence of established players such as 10x Genomics and NanoString Technologies, alongside emerging companies developing innovative spatial omics technologies. This dynamic ecosystem is indicative of a field ripe for continued innovation and expansion. Recent developments include: March 2024: 10x Genomics initiated commercial distribution of its eagerly anticipated Visium HD Spatial Gene Expression instrument. Visium HD is engineered to empower researchers with the ability to thoroughly analyze FFPE tissue samples by quantifying spatial gene expression across the entire transcriptome at a single-cell resolution., January 2024: SimBioSys obtained 510(k) clearance from the US Food and Drug Administration (FDA). This clearance permits the marketing of TumorSight Viz, a software application designed to generate three-dimensional spatial visualizations of breast tumors.. Key drivers for this market are: High Burden of Cancer and Genetic Diseases, Advancement in Omics Technologies and Increasing Demand for Personalized Medicine; Rising Government Initiatives and Funding Activities. Potential restraints include: High Burden of Cancer and Genetic Diseases, Advancement in Omics Technologies and Increasing Demand for Personalized Medicine; Rising Government Initiatives and Funding Activities. Notable trends are: The Spatial Transcriptomics Segment is Expected to Hold a Significant Market Share Over the Forecast Period.

The original data used in the article: Development of Multiomics in situ Pairwise Sequencing (MiP-Seq) for Single-cell Resolution Multidimensional Spatial Omics

Delineating the spatial multiomics landscape will pave the way to understanding the molecular basis of physiology and pathology. However, current spatial omics technology development is still in its infancy. Here, we developed a high-throughput targeted in situ sequencing strategy, multiomics in situ pairwise sequencing (MiP-Seq), to efficiently decipher multiplexed DNAs, RNAs, proteins, and small biomolecules at subcellular resolution. MiP-Seq simultaneously sequenced the dual barcode base of padlock probes, dramatically increasing the detection capacity to 10N by N rounds of sequencing. We delineated spatial gene profiles in the hypothalamus using MiP-Seq. Moreover, MiP-Seq was unitized to detect tumor gene mutations and allele-specific expression of parental genes and to differentiate sites with and without the m6A RNA modification at specific sites. MiP-Seq was combined with in vivo Ca2+ imaging and Raman imaging to obtain a spatial multiomics atlas correlated to neuronal activity and cellular biochemical fingerprints. Importantly, we proposed a “signal dilution strategy” to resolve the crowded signals that challenge the applicability of in situ sequencing. Together, our method improves spatial multiomics and precision diagnostics, and facilitates analyzing cell function in connection with gene profiles.

The spatial genomics and transcriptomics market is experiencing robust growth, driven by the increasing need for high-resolution spatial profiling of biological samples. This technology allows researchers to understand the complex interplay between cells and their microenvironment, providing crucial insights into disease mechanisms, drug development, and fundamental biological processes. The market's expansion is fueled by several key factors, including advancements in imaging technologies, the development of novel spatial omics platforms, and the growing adoption of these techniques across diverse research areas such as oncology, immunology, and neuroscience. The market is segmented by application (hospital, laboratory, other), type (instruments, consumables, software), and region, with North America currently holding a significant market share due to its well-established research infrastructure and high adoption rate of cutting-edge technologies. The substantial investment in research and development by key players like Illumina, 10x Genomics, and NanoString Technologies further contributes to market growth. The market is anticipated to witness a competitive landscape, with companies focusing on developing innovative products and expanding their geographical reach to capture a larger market share. Consumables are expected to dominate the market due to their recurring revenue nature. The projected Compound Annual Growth Rate (CAGR) signifies a promising trajectory for this field. While the precise CAGR is not provided, considering the technological advancements and increasing adoption in various research areas, a conservative estimate of 15-20% CAGR over the forecast period (2025-2033) is plausible. Challenges such as high instrument costs, complex data analysis requirements, and the need for specialized expertise could potentially restrain market growth to some extent. However, the continuous development of user-friendly software and data analysis tools coupled with an increasing number of skilled professionals is likely to mitigate these limitations, driving sustained market expansion. Furthermore, the development of more affordable and accessible spatial omics technologies will expand market penetration in research settings with limited budgets, significantly contributing to future market expansion.

Snapshot img

Spatial Genomics And Transcriptomics Market Size 2025-2029

The spatial genomics and transcriptomics market size is forecast to increase by USD 732.3 million, at a CAGR of 12% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing adoption of spatial genomics in drug discovery. This innovative approach allows for a more precise understanding of the spatial organization of cells, enabling the identification of new targets and biomarkers for disease diagnosis and treatment. Furthermore, the use of spatial omics is gaining traction in biomarker identification, offering potential for personalized medicine and improved patient outcomes and in therapeutic areas like neurological disorders, infectious diseases, neuroscience, immunology, genomics, and proteomics. However, the market faces challenges, including the lack of workforce expertise in spatial genomics. As this field continues to evolve, there is a pressing need for skilled professionals to drive research and development efforts.
Companies seeking to capitalize on the opportunities in this market must invest in workforce development and collaborate with academic institutions and industry partners to build a strong foundation for future success. The ability to navigate these challenges and harness the power of spatial genomics will be crucial for companies looking to gain a competitive edge in the life sciences industry.

What will be the Size of the Spatial Genomics And Transcriptomics Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in technologies and applications across various sectors. Cell signaling, confocal microscopy, RNA extraction, and sample preparation are integral components of this dynamic landscape. Ethical considerations are increasingly becoming a focus, as the use of high-throughput sequencing and data visualization tools uncovers new insights into genomic data. In situ sequencing and software solutions facilitate pathway analysis and data integration, enabling a more comprehensive understanding of biological processes. RNA extraction and sample preparation techniques play a crucial role in the market, ensuring accurate and reliable data. High-throughput sequencing technologies, such as next-generation sequencing (NGS), have revolutionized genome editing and disease modeling by providing vast amounts of genomic data.

Data repositories and machine learning algorithms facilitate data interpretation and gene regulatory network analysis. The continuous unfolding of market activities includes the development of spatial transcriptomics platforms, which offer three-dimensional genome organization insights. Microfluidic devices and protein-DNA interactions are also gaining attention, as they enable precise manipulation of biological samples. Quantitative PCR (qPCR) and chromatin conformation capture techniques complement these advancements, providing additional layers of information. The integration of various technologies, such as microarray technology, fluorescence microscopy, and data visualization tools, offers a more holistic approach to understanding complex biological systems. Spatial genomics and transcriptomics applications extend to drug discovery and gene expression analysis, providing valuable insights into cellular processes and biological pathways.

In conclusion, the market is characterized by continuous innovation and evolving patterns. The integration of various technologies, including cell signaling, confocal microscopy, RNA extraction, sample preparation, ethical considerations, high-throughput sequencing, data visualization, in situ sequencing, software solutions, pathway analysis, data integration, microfluidic devices, protein-DNA interactions, next-generation sequencing, gene regulatory networks, and more, offers a more comprehensive understanding of biological systems. This knowledge drives progress in personalized medicine, biomarker discovery, genome editing, disease modeling, and other sectors.

How is this Spatial Genomics And Transcriptomics Industry segmented?

The spatial genomics and transcriptomics industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.ProductConsumablesInstrumentsEnd-userTranslational researchAcademic customersDiagnostic customersPharmaceutical manufacturerApplicationDrug Discovery & DevelopmentDisease Research (Oncology, Neuroscience)Biomarker IdentificationTechniqueSpatial Transcriptomics (e.g., Visium, MERFISH)Spatial GenomicsProteomics (Spatial Proteomics)GeographyNorth AmericaUSCanadaEuropeFranceGermanyItalyUKMiddle East and Afr

Additional file 2:Table S1. Cell counts of the adult and fetal tissue groups at each omics level. Table S2. Filtered matrix raw read counts for scRNA-Seq across tissues in both fetal and adult groups. Cell_Count_Filtered_Matrix column represents raw read counts initially obtained from published studies or after filtering for the removal of background noises. Table S3. Statistics of the upregulated genes from adult and fetal tissues, filtered by average Log2FoldChange > 0.25 and adjusted P of 0.05. Clusters represent cell types. Genes were ranked by average log2-fold-change. Table S4. Top receptor–ligand interaction profiles of the cell types in the 38 matching adult and fetal tissues. Interaction analysis was done separately for each tissue, and information on the interaction pairs can be viewed from the first column. Table S5: Top clonotypes (VDJ gene combinations) of each cell type present in the T and B cell repertoires. Table S6. Top TFs in the pseudotime transitions of adult and fetal colon cell types. Table S7. Top receptor-ligand pairs in spatial transcriptomics of adult colons (colon 1 and colon 2) as well as in scRNA-seq adult and fetal colons. The first column represents the data type to which the interactions belong. Table ranked by decreasing interaction ratios. Table S8. Comparison of SCA with other single-cell omics databases. Green tick indicates a yes and a red cross indicates a no. Table S9. List of public resources included in the SCA database portal. SCA_PID refers to SCA-designated project identity number (PID).

Visium spatial transcriptomics (10X Genomics) performed on 4 CCA samples. Each sample has two paired-end sequencing runs: the first (I1 & I2) are a pair reading indexes; the second (R1 & R2) are a pair reading inserts, with R1 additionally reading 10X barcodes. For histology images, please contact authors.

The size of the spatial omics market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of XXX% during the forecast period. The significant growth of the spatial omics market is attributed to the increasing demand for spatial information in various biological research applications, advancements in spatial omics technologies, rising investments in research and development, and growing collaborations and partnerships among industry players. The market is also driven by the increasing adoption of spatial omics techniques in various fields, including drug discovery, cancer research, and personalized medicine. Recent developments include: In February 2024, DNAnexus, Inc., collaborated with Curio Bioscience to streamline and simplify data analysis for high-resolution, whole transcriptome spatial mapping studies, allowing Curio Bioscience to utilize the DNAnexus Precision Health Data Cloud and its intuitive analysis environment., In June 2023, OMAPiX entered into a strategic partnership with spatial biology platform providers Vizgen, Inc., Ultivue, Inc., and Resolve Biosciences to accelerate life science research and drug development..

The global spatial OMICS market size was worth more than USD 307.7 million in 2024 and is poised to witness a CAGR of over 10.9%, crossing USD 1.18 billion revenue by 2037. Diagnostics segment is anticipated to dominate with 41.2% industry share, fueled by improved detection accuracy and genome data availability.